QUANTIFYING THE BENEFITS OF AUTOMATION

Process automation, CIM and paperless manufacturing are operational st rategies being developed to support the changing business strategies i n pharmaceuticals. Present FDA activities appear to make automation an attainable GMP regulatory reality. Operations are being required to p rovide greater benefits in the form of efficiencies, manpower rational ization, and productivity gains in order to justify new CIM and automa tion projects. This paper describes where benefits have been identifie d and quantified in operational environments.